Recombinant Protein Production News and Research

RSS

Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins

In a joint effort to provide lower cost and more defined reagents and media to the cell and gene therapy market, Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media solutions for the cell and gene therapy industry, has signed a manufacturing, distribution, and collaboration agreement with Core Biogenesis, an innovator in the field of recombinant human proteins expressed in plants.

From Nucleus Biologics 24 Jan 2024

Sino Biological Announces the Opening of Its New US-Based Center for Bioprocessing

Sino Biological, Inc. is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.

From Sino Biological Inc. 9 Oct 2023

Difficult transmembrane protein targets for therapeutic antibodies

In this interview, News-Medical talks to Sylvia Xie, product scientist at Sino Biological, about the ongoing emergence of transmembrane proteins as targets for therapeutic antibodies.

From Sino Biological Inc. 12 Jul 2023

Advances in influenza research

This interview with Dr. Mohammad S Safiarian, Associate Product Manager at Sino Biological, discusses the advances in influenza research and how effective vaccines are developed.

From Sino Biological Inc. 30 Jun 2023

Sino Biological announces construction of its new US-based center for bioprocessing

Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing at its Levit Green facility in Houston, Texas USA.

From Sino Biological Inc. 24 Nov 2022

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

In this interview, Dr. Shebna Massey discusses neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and more. She also discusses and explores new therapeutic targets and biomarkers for these diseases.

From Sino Biological Inc. 26 Oct 2022

Universal vaccine advancement through AI and recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng and Dr. Lurong Pan about how AI computing can be used in combination with high throughput production and screening to enhance the development process for potential universal vaccines.

From Sino Biological Inc. 3 Oct 2022

Developing and manufacturing custom recombinant antibodies for R&D

In this interview, Dr. Linlin Zhang, technical specialist for Sino Biological Europe, discusses how Sino is expanding its product offerings into the European market and outlines its process for developing and manufacturing custom recombinant antibodies for their clients.

From Sino Biological Inc. 6 Apr 2022

ProteoGenix launches new XtenCHOTM Transient CHO Expression System to improve biologics development

ProteoGenix, a contract research organization specialized in biologics discovery and bioproduction, announces the launch of its XtenCHOTM Transient Expression System.

From ProteoGenix 30 Mar 2022

Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services

Sino Biological is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.

From Sino Biological Inc. 24 Mar 2022

Sino Biological Invests Over 200M RMB to Establish New Subsidiaries in Taizhou and Suzhou, China.

Sino Biological is pleased to announce the formation of two new operationally-focused subsidiaries in China.

From Sino Biological Inc. 14 Mar 2022

Current and future perspectives of mRNA technology

New research reports on the current and future perspectives on messenger ribonucleic acid technology, the platform on which the first successful COVID-19 vaccine was based.

8 Mar 2022

Providing recombinant antibody services and more within Europe

In this interview, News-Medical talks to Dr. Zhang Linlin, Technical Specialist at Sino Biological Europe, about their recombinant antibody services and more that they can provide within Europe. Image credit: Corona Borealis Studio/Shutterstock.com

From Sino Biological Inc. 11 Jan 2022

Sino Biological Establishes New Location in Houston, Texas

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.

From Sino Biological Inc. 4 Jan 2022

Providing quick & efficient CRO services with Sino Biological

In this interview, News-Medical talks to Dr. Lin Yutao, head of project management at Sino Biological, about the work she does and how Sino provides quick and efficient recombinant CRO services.

From Sino Biological Inc. 15 Dec 2021

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

A new study aimed to identify several potent neutralizing RBD-directed and NTD-directed mAbs that used a nanoparticle displaying the S glycoprotein to capture SARS-CoV-2-specific B cells.

2 Nov 2021

Adapting biological research and development to COVID-19

In this interview, News-Medical talks to Dr Yuning Chen, about the work he does with Sino Biological and how they have adapted their research & development to the COVID-19 pandemic.

From Sino Biological Inc. 8 Oct 2021

New book focuses on rational drug design and discovery

Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery.

25 Feb 2021

Game-Changer: A SARS-CoV-2 serological test for 50-cents per sample!

A recent study published in the preprint server medRxiv in July 2020 shows that this is indeed possible. The development of this inexpensive but reliable and sensitive test could change the face of preventive measures for COVID-19 in low-resource settings.

17 Jul 2020

Immune responsive nanoparticles for COVID-19 vaccine delivery

Analytik reports how the renowned Quadram Institute has invested in a ZetaView Nanoparticle Tracking Analyser to help them develop a new approach for vaccine delivery based on engineering the natural ability of resident gut bacteria to generate nanoparticle sized Outer Membrane Vesicles.

From Analytik Ltd 4 Jun 2020